Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Neuron · 2023-09 · 111 (18) · 2781-2799
DOI: 10.1016/j.neuron.2023.05.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuron, 2023-09. Verfasst von Harald Hampel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Disease and Brain Health, Eisai Inc., Nutley, NJ, USA. Electronic address: harald_hampel@eisai.com. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 289-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Timely detection of the pathophysiological changes and cognitive impairment caused by Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker-guided targeted therapies that may be most effective when provided early in the disease. Currently, diagnosis and management of early AD are largely guided by clinical symptoms. FDA-approved neuroimaging and cerebrospinal fluid biomarkers can aid detection and diagnosis, but the clinical implementation of these testing modalities is limited because of availability, cost, and perceived invasiveness. Blood-based biomarkers (BBBMs) may enable earlier and faster diagnoses as well as aid in risk assessment, early detection, prognosis, and management. Herein, we review data on BBBMs that are closest to clinical implementation, particularly those based on measures of amyloid-β peptides and phosphorylated tau species. We discuss key parameters and considerations for the development and potential deployment of these BBBMs under different contexts of use and highlight challenges at the methodological, clinical, and regulatory levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Alzheimer's Disease and Brain Health, Eisai Inc., Nutley, NJ, USA. Electronic address: harald_hampel@eisai.com.
- Alzheimer's Disease and Brain Health, Eisai Inc., Nutley, NJ, USA. Electronic address: helen_hu@eisai.com.
- Chambers-Grundy Center for Transformative Neuroscience, Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas…
- Center for Improving Chronic Illness Care, University of Southern California, Los Angeles, CA, USA.
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Biomarker Research, National Center for Geriatrics and Gerontology, Obu, Japan; Department of Cognition and Behavior Science, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
Zitieren
APA
Hampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O'Bryant, S., Shaw, L. M., Cho, M., Batrla, R., Vergallo, A., Blennow, K., Dage, J., & Schindler, S. E. (2023). Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape. Neuron, 111(18), 2781-2799. https://doi.org/10.1016/j.neuron.2023.05.017
Vancouver
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, et al. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape. Neuron. 2023;111(18):2781-2799. doi:10.1016/j.neuron.2023.05.017
BibTeX
@article{Hampel2023,
author = {Hampel, Harald and Hu, Yan and Cummings, Jeffrey and Mattke, Soeren and Iwatsubo, Takeshi and Nakamura, Akinori and Vellas, Bruno and O'Bryant, Sid and Shaw, Leslie M and Cho, Min and Batrla, Richard and Vergallo, Andrea and Blennow, Kaj and Dage, Jeffrey and Schindler, Suzanne E},
title = {Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape},
journal = {Neuron},
year = {2023},
volume = {111},
number = {18},
pages = {2781--2799},
doi = {10.1016/j.neuron.2023.05.017}
}
EUVIMED